Notably, glucagon-like peptide-1 receptor agonists (GLP-1RAs) can potentiate the activity of DMH GLP-1R neurons
Diabetes Obes Metab (2018) 20:22109
A provider-guided approach combining genetic insights, baseline biomarker assessment, and your individual health history enables more precise conversations about whether .25mg dosing aligns with your metabolic profile and treatment goals
Effective January 1, 2026, Medi-Cal Rx is excluding coverage for GLP-1 medications prescribed for weight loss: [12] Wegovy, Zepbound, Saxenda: Completely removed from the Contract Drugs List for weight loss Ozempic, Mounjaro, Rybelsus: Restricted to Type 2 diabetes onlyweight loss claims will auto-deny Existing prior authorizations end December 31, 2025 Exceptions: Members under age 21 may still qualify via EPSDT Non-weight-loss indications (Zepbound for OSA, Wegovy for cardiovascular) may still get PA approval This does NOT affect Kaiser commercial or employer-sponsored plansonly Medi-Cal members
Additionally, S100B and S100A6 interact with different extracellular structural domains of RAGE
